March 30, 2021 -- GlaxoSmithKline (GSK) has signed an agreement in principle to support manufacturing of up to 60 million doses of Novavax's NVX-CoV2373 COVID-19 vaccine candidate for use in the U.K.
Beginning as early as May, GSK will provide fill and finish manufacturing capacity at its Barnard Castle facility in the northeast of England. The parties, which include GSK, Novavax, and the U.K. Government Vaccines Taskforce, will negotiate a final agreement to include additional terms and conditions, GSK said.
The vaccine is expected to be submitted for regulatory review in the U.K. during the second quarter.